{"schema_version":"1.0","type":"article","title":"Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena","url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.md","lang":"en","date":"2026-06-04","publish_at":"2026-06-04T10:30:00+08:00","updated_at":"2026-06-04","category":"商業分析系列","topic":"公司研究","tags":["Company Research","Obesity medicine","Big Pharma","Biotech business analysis","Drug development"],"summary":"Retatrutide pushes obesity-drug efficacy toward surgery-level territory, but the real competitive battle will be durability, tolerability, body composition, comorbidity benefit, and access.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-04）。Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena。https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}